Phase I trial of 90Y-ibritumomab tiuxetan i patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation

Leukemia and Lymphoma

Volumn 48, Issue 4, 2007, Pages 683-690

  Vose, Julie M ^a   Bierman, Philip J ^a   Loberiza, Fausto R ^a   Bociek, Robert G ^a   Matso, Daniel ^b   Armitage, James O ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b BIOGEN   (United States)

Author keywords

Autologous stem cell transplantation; High dose chemotherapy; Ibritumomab tiuxetan; Non Hodgkin's lymphoma; Radio immunotherapy

Indexed keywords

ANTIBIOTIC AGENT; DIPHENHYDRAMINE; FLUDARABINE; IBRITUMOMAB TIUXETAN; PARACETAMOL; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; BLOOD TOXICITY; BRONCHITIS; CANCER STAGING; CANDIDIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HEMOPTYSIS; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOXIA; LEUKOPENIA; LYMPHADENITIS; MALE; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PAIN; PHARYNGITIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RADIOIMMUNOTHERAPY; RISK FACTOR; STOMATITIS; SURVIVAL RATE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; UNIVARIATE ANALYSIS; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; YTTRIUM RADIOISOTOPES;

EID: 34247189654     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601158639     Document Type: Article

References (40)

1. Shipp, M. A., Abeloff, M. D., Antman, K. H., Carroll, G., Hagenbeek, A. and Loeffler, M. (1999) International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive Non-Hodgkin's lymphomas: Report of the jury. J Clin Oncol, 17, pp. 423-429.
2. Vose, J. M., Zhang, M. J., Rowlings, P. A., Lazarus, H. M., Bolwell, B. J. and Freytes, C. O. (2001) Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol, 19, pp. 406-413.
3. Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van Der Lelie, H. and Bron, D. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med, 333, pp. 1540-1545.
4. Kewalramani, T., Zelenetz, A. D., Nimer, S. D., Portlock, C., Straus, D. and Noy, A. (2004) Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood, 103, pp. 3684-3688.
5. Moskowitz, C. H., Bertino, J. R., Glassman, J. R., Hedrick, E. E., Hunte, S. and Coady-Lyons, N. (1999) Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol, 17, pp. 3776-3785.
6. Hamlin, P. A., Zelenetz, A. D., Kewalramani, T., Qin, J., Satagopan, J. M. and Verbel, D. (2003) Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood, 102, pp. 1989-1996.
7. Rapoport, A. P., Rowe, J. M., Kouides, P. A., Duerst, R. A., Abbond, C. N. and Liesveld, J. L. (1993) One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: Value of pretransplant disease status for predicting outcome. J Clin Oncol, 11, pp. 2351-2361.
8. Guglielmi, C., Gomez, F., Philip, T., Hagenbeek, A., Martelli, A. and Sebban, C. (1998) Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol, 16, pp. 3264-3269.
9. Corradini, P., Ladetto, M., Zallio, F., Astulfi, M., Rizzo, E. and Sametti, S. (2004) Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol, 22, pp. 1460-1468.
10. Lenz, G., Dreyling, M., Schiegnitz, E., Forstpointer, R., Wandt, H. and Freund, M. (2004) Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood, 104, pp. 2667-2674.
11. Schouten, H. C., Qian, W., Kvaloy, S., Porcelline, A., Hagberg, H. and Johnsen, H. E. (2003) High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol, 21, pp. 3918-3927.
12. Kewalramani, T., Nimer, S. D., Zelenetz, A. D., Malhotra, S., Qin, J. and Yahalom, J. (2003) Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant, 32, pp. 673-679.
13. Kuittinen, T., Wiklund, T., Remes, K., Elonen, E., Lehtinen, T. and Kuiltinen, O. (2005) Outcome of progressive disease after autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: A nation-wide survey. Eur J Haematol, 75, pp. 199-205.
14. Vose, J. M., Bierman, P. J., Anderson, J. R., Kessinger, A., Pierso, J. and Nelson, J. (1992) Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: Clinical course and patient follow-up. Blood, 80, pp. 2142-2148.
15. Paltiel, O., Rubinstein, C., Nagler, A., Gordon, L. and Deutsch, L. (2003) Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma. Bone Marrow Transplant, 31, pp. 565-569.
16. Davies, A. J., Rohatiner, A. Z., Howell, S., Britton, K. E., Owens, S. E. and Micallef, I. N. (2004) Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol, 22, pp. 1469-1479.
17. Gordon, L. I., Witzig, T., Molina, A., Czuczman, M., Emmanouilides, C. and Joyce, R. (2004) Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma, 5, pp. 98-101.
18. Gordon, L. I., Molina, A., Witzig, T., Emmanouilides, M., Raubtischek, A. and Darif, M. (2004) Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study. Blood, 103, pp. 4429-4431.
19. Horning, S. J., Younes, A., Jain, V., Kroll, S., Lucas, J. and Podoloff, D. (2005) Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol, 23, pp. 712-719.
20. Schilder, R., Molina, A., Bartlett, N., Witzig, T., Gordon, L. and Murray, J. (2004) Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm, 19, pp. 478-481.
21. Vose, J. M., Wahl, R. L., Saleh, M., Rohatines, A. Z., Knox, S. J. and Radford, J. A. (2000) Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol, 18, pp. 1316-1323.
22. Witzig, T. E., Flinn, I. W., Gordon, L. I., Emmanonilides, C., Czuczman, M. S. and Saleh, M. N. (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol, 20, pp. 3262-3269.
23. Fisher, R. I., Kaminski, M. S., Wahl, R. L., Knox, S. J., Zelenetz, A. D. and Vose, J. M. (2005) Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol, 23, pp. 7565-7573.
24. Wiseman, G. A. and Witzig, T. E. (2005) Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm, 20, pp. 185-188.
25. (2005) Zevalin (Ibritumomab Tiuxetan) Prescribing Information, Biogen Idec, Cambridge, MA
26. Jacobs, S. A., Vidnovic, N., Joyce, J., McCook, B., Torok, F. and Avril, N. (2005) Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Clin Cancer Res, 11, pp. 7146s-7150s.
27. Kaminski, M. S., Estes, J., Zasadny, K. R., Francis, I. R., Ross, C. W. and Tuck, M. (2000) Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood, 96, pp. 1259-1266.
28. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I. and Connors, J ML (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol, 17, p. 1244.
29. Kaplan, E. L. and Meier, P. (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53, pp. 457-481.
30. Cox, D. R. (1972) regression models and life tables. J R Stat Soc B, 34, pp. 187-220.
31. Kaya, H., Keung, Y. K., Case, D., Cruz, J. M., Perry, J. J. and Radford, J. E. (2002) Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant, 8, pp. 544-549.
32. McLaughlin, P., Grillo-Lopez, A. J., Link, B. K., Levy, R., Czuczman, M. S. and Williams, M. E. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol, 16, pp. 2825-2833.
33. Brugger, W., Hirsch, J., Grunebach, F., Repp, R., Brossart, P. and Vogel, W. (2004) Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: A prospective, multicenter phase II study. Ann Oncol, 15, pp. 1691-1698.
34. Khouri, I. F., Saliba, R. M., Hosing, C., Okoroji, G. J., Acholonu, S. and Anderini, P. (2005) Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol, 23, pp. 2240-2247.
35. Emmanouilides, C., Witzig, T. E., Gordon, L. I., Wiseman, G. and Flinn, I. (2006) Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma, 47, pp. 629-636.
36. Gregory, S. A., Leonard, J. P., Vose, J. M., Zelenetz, A. D., Horning, S. J. and Know, S. J. (2005) Superior outcomes associated with earlier use: Experience with tositumomab and iodine I 131 tositumomab in 1,177 patients (pts) with low-grade, follicular, and transformed non-Hodgkin's lymphoma (NHL) (Abstract 6561). Proc Am Soc Clin Oncol, 23, p. 575s.
37. Kaminski, M. S., Tuck, M., Estes, J., Kolstad, A., Ross, C. N. and Zasadny, K. (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med, 352, pp. 441-449.
38. Shipley, D. L., Greco, F. A., Spigel, D. R., Edwards, D., Mayfield, M. and Yost, K. (2005) Rituximab with short duration chemotherapy followed by 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: Update of a Minnie Pearl Cancer Research Network phase II trial (Abstract 6577). Proc Am Soc Clin Oncol, 23, p. 579s.
39. Sweetenham, J. W., Dicke, K., Arcaroli, J., Kogel, K., Rana, T. M. and Rice, L. L. (2004) Efficacy and safety of Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) therapy with rituximab maintenance in patients with untreated low-grade follicular non-Hodgkin's lymphoma (Abstract 2633) (abstr). Blood, 104, p. 720a.
40. Ansell, S. M., Schilder, R. J., Pieslor, P. C., Gordon, L. and Emmanouilides, C. (2004) Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: A review of the literature. Clin Lymphoma, 5, pp. 202-204.